Every Form 4 that Latigo Biotherapeutics, Inc. (LTGO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow LTGO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LTGO filings page.
Latigo Biotherapeutics, Inc. (LTGO) reports that funds affiliated with 5AM converted preferred shares into common stock in connection with Latigo’s initial public offering. On August 10, 2026, 5AM Ventures VI, L.P. and 5AM Opportunities II, L.P. converted their Series A, Series A-2 and Series B Preferred Stock into an aggregate of common shares on a one-for-one basis for no additional consideration, leaving the preferred positions at zero. Following these automatic conversions immediately prior to the IPO closing, 5AM Ventures VI, L.P. holds 4,975,543 common shares indirectly and 5AM Opportunities II, L.P. holds 2,350,419 common shares indirectly. Control and beneficial ownership are described through 5AM’s general partner entities, with Dr. Kush Parmar and Andrew J. Schwab disclaiming beneficial ownership except to the extent of their pecuniary interests.
Latigo Biotherapeutics, Inc. (LTGO) received a Form 4 from several affiliated Foresite Capital funds, all reporting as ten percent owners. On August 10, 2026, they reported the conversion of 9,041,328 derivative securities (preferred stock and a convertible note) into an equal number of common shares, largely in connection with Latigo’s initial public offering as described in the footnotes. The same day, an affiliated fund also purchased 140,000 shares of common stock at $18.00 per share, all held indirectly through the funds, with each reporting person disclaiming beneficial ownership beyond its pecuniary interest.
Latigo Biotherapeutics, Inc. (LTGO) reported that director Todd N. Smith received a grant of stock options for 105,542 shares of common stock. The options have an exercise price of $18.00 per share, expire on August 5, 2036, and were acquired as a director stock option award. All 105,542 options are held directly and will vest in 36 equal monthly installments after May 30, 2026.
Latigo Biotherapeutics, Inc. (LTGO) reported that entities affiliated with director and ten percent owner James B. Tananbaum converted multiple preferred stock series and a convertible promissory note into common stock, largely in connection with the closing of Latigo’s initial public offering, and also purchased additional common shares. Foresite Capital funds converted an aggregate of 9,041,328 derivative-based shares into common stock through automatic conversions, and a Foresite fund separately bought 140,000 common shares at $18.00 per share. All positions are held indirectly through Foresite Capital funds, which, together with the reporting person, disclaim beneficial ownership beyond their pecuniary interests.